Financings in Brief: Beckman Instruments
This article was originally published in The Gray Sheet
Executive Summary
Beckman Instruments: Issues $100 mil. in debentures due June 1, 2026 at an interest rate of 7.05%. Proceeds will be used to fund "general corporate purposes and to repay the company's existing commercial paper borrowings," Beckman says. Beckman filed a registration statement with the Securities and Exchange Commission in April for issuance of up to $200 mil. in debt securities. The company says it "currently has no plans to issue the remaining $100 mil." covered by the SEC filing...
You may also be interested in...
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
World-First Nod For Yuhan's Lung Cancer Drug, In Korea
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes Gains US FDA Clearance For Velys Robot For Total Knee Surgery
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: